 | | Vol. 6.38 – 2 November, 2020 |
| |
|
|
| Scientists demonstrated a general strategy to fabricate personalized nanovaccines based on a cationic fluoropolymer for post-surgical cancer immunotherapy.
[Nature Nanotechnology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| | DERMAL STEM CELLS & TISSUE REGENERATION |
| | Fibroblast growth factor (FGF) 2, also called basic FGF, had the potential to accelerate wound closure by activating vascular endothelial cells and fibroblasts. Researchers examined the effects of FGF2 on keratinocyte morphology and epithelial–mesenchymal transition in wounded skin.
[Scientific Reports] |
| | Investigators focused on microRNA-200b/c-3p whose expression was abundant in intact epidermis, but dramatically decreased in skin wounds.
[Cell Death Discovery] |
| | Scientists tested whether nonanal, a scent compound from plants, stimulated growth factors in dermal papilla cells (DPCs) and delineated the underlying mechanisms involved. They found that nonanal promoted DPC proliferation in a dose-dependent manner.
[International Journal of Molecular Sciences] |
| | By using a human skin equivalent (HSE), the horizontal tension-force balance of the dermal layer was found to clearly improve HSE characteristics, such as the physical relationship between cells and the extracellular matrice.
[Communications Biology] |
| |
|
|
| Researchers demonstrated that ABL1/2 kinase activities and/or expression were potentiated in cell lines and patient samples following resistance, and ABL1/2 drove BRAF and BRAF/MEK inhibitor resistance by inducing reactivation of MEK/ERK/MYC signaling.
[Nature Communications] |
|
|
|
| In BRAFV600E melanomas, RAF and MEK inhibitors efficiently block oncogenic signaling, but persister cells emerge. Scientists showed that persister cells escaped drug-induced cell-cycle arrest via brief, sporadic ERK pulses generated by transmembrane receptors and growth factors operating in an autocrine/paracrine manner.
[Cell Systems] |
|
|
|
| The authors examined the anti-cancer efficacy of salinomycin (Sal) in melanoma cell lines, and found six of eight cell lines were sensitive to Sal.
[Scientific Reports] |
|
|
|
| Investigators examined the role of Trichohyalin-like 1 (TCHHL1) protein in normal human keratinocytes (NHKs) and squamous cell carcinoma. The knockdown of TCHHL1 by transfection with TCHHL1 siRNA significantly inhibited proliferation and induced the early apoptosis of NHKs.
[Cell Death Discovery] |
|
|
|
| Researchers found that p16ink4a immunoreactivity was not restricted to melanocytes but also existed in fibroblasts; the number of p16ink4a-positive fibroblasts was significantly increased in lesional skin compared to perilesional skin and normal controls.
[Diagnostics] |
|
|
|
|
| The authors focus on the major alterations affecting lipid storage organelles and lipid metabolism, discuss how glycerophospholipids, sphingolipids, sterols and eicosanoids metabolic dysregulations contribute to the phenotype plasticity of melanoma cells and/or melanoma aggressiveness.
[Cancers] |
|
|
|
| Investigators describe the functional characterization of acetylcholine receptors in different tumor types, placing attention on melanoma, and highlight how cholinergic receptors both of muscarinic and nicotinic type can play a relevant role in the migratory processes of melanoma cells.
[Cancers] |
|
|
|
|
| MediWound Ltd completed the enrollment stage of its NexoBrid® Phase III pediatric clinical study. The completion of the study enrollment stage followed the FDA’s recent agreement to allow the NexoBrid® expanded access protocol to be expanded to include pediatric as well as adult burn patients.
[MediWound Ltd] |
|
|
|
| OliX Pharmaceuticals, Inc. announced that the US FDA cleared the company’s Investigational New Drug application to evaluate the efficacy of OLX10010 as an adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery.
[OliX Pharmaceuticals, Inc. (Globe Newswire Inc)] |
|
|
|
|
| November 11 – November 13
Virtual |
|
|
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
| | Pfizer – New York City, New York, United States |
|
|
|
| | IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
| | University of Alabama at Birmingham – Birmingham, Alabama, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
